Medicine shortages, fragile sourcing and last‑minute firefighting are now routine features of practice across community and hospital pharmacy in Great Britain. Pharmacists are left managing the consequences at the sharp end, often with limited visibility of how and why supply has failed. My book, Transforming the Pharmaceutical Supply Chain, argues that these problems are not inevitable — they are the predictable result of how we design, govern and incentivise pharmaceutical supply chains from first‑in‑human studies through to routine NHS care.
The book takes a whole–systems view of the modern medicines supply chain, tracing how decisions in discovery, development, outsourcing and regulation accumulate into structural fragility. Rather than treating “the supply chain” as a downstream logistics issue, it shows how choices on clinical development models, contract manufacturing, quality management and commercial strategies lock in risk years before a product reaches the dispensary. Drawing on case examples and my experience in development and supply roles, the book examines how consolidation, long globalised networks and an overriding focus on financial engineering have eroded resilience and transparency.
For practising pharmacists in the UK, three themes may be particularly relevant:
- First, the book reframes shortages as a systems failure rather than an inventory failure. Understanding upstream causes helps explain why local “work-arounds” so often prove temporary and why similar patterns recur across very different products;
- Second, it highlights the consequences of opaque, multi‑tier outsourcing structures in which legal accountability and operational control can be widely separated, both within and outside the UK. This opacity makes it harder for regulators, commissioners and frontline professionals to anticipate disruption or to hold the right actors to account when it occurs;
- Third, the book explores how better integration of development, manufacturing and supply chain thinking — supported by modern data and planning tools — could enable smaller, more responsive networks that are closer to patients and health systems.
The argument is unapologetically reform‑oriented. I suggest concrete steps for regulators, policymakers and industry leaders to rebalance incentives towards resilience, openness and public value. These include reshaping procurement and reimbursement to reward assured supply and high‑integrity sourcing, strengthening expectations for supply‑chain transparency, and encouraging development and manufacturing models that keep critical knowledge and capability closer to the NHS and its partners.
Pharmacists — as medicines experts and stewards of finite system resources — are well placed to contribute to this conversation, whether through formulary work, local procurement, medicines optimisation or national policy roles.
My hope is that this book will be useful not only to colleagues in industry, but also to pharmacists involved in commissioning, education and policy who wish to move beyond managing the symptoms of supply chain failure and start addressing root causes. If we are serious about providing patients with reliable access to safe, effective medicines in the coming decades, we will need to rethink how we design, govern and measure pharmaceutical supply chains. I would be delighted if this book helps stimulate that debate within the UK pharmacy community.
Hedley Rees
